2023-05-17 12:04 | CC:RVX | Resverlogix Corp | 0.13 | Warrants Expire110 | Resverlogix warrants to expire June 7 |
2023-05-11 18:11 | CC:RVX | Resverlogix Corp | 0.14 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-05-11 18:11 | CC:RVX | Resverlogix Corp | 0.14 | SEDAR MD & A815 | SEDAR MD & A |
2023-03-31 19:28 | CC:RVX | Resverlogix Corp | 0.145 | SEDAR MD & A815 | SEDAR MD & A |
2023-03-31 19:26 | CC:RVX | Resverlogix Corp | 0.145 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
2023-03-31 19:20 | CC:RVX | Resverlogix Corp | 0.145 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |
2023-03-20 11:49 | CC:RVX | Resverlogix Corp | 0.16 | News Release200 | Resverlogix closes one-year extension of debenture |
2023-03-02 13:15 | CC:RVX | Resverlogix Corp | 0.155 | News Release200 | Resverlogix publishes 2 articles in scientific journals |
2022-11-11 18:06 | CC:RVX | Resverlogix Corp | 0.19 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-11-11 18:06 | CC:RVX | Resverlogix Corp | 0.19 | SEDAR MD & A815 | SEDAR MD & A |
2022-09-28 10:45 | CC:RVX | Resverlogix Corp | 0.205 | News Release200 | Resverlogix to focus apabetalone work on long COVID |
2022-08-22 10:08 | CC:RVX | Resverlogix Corp | 0.25 | News Release200 | Resverlogix publishes apabetalone data in journal |
2022-08-15 18:48 | CC:RVX | Resverlogix Corp | 0.27 | News Release200 | Resverlogix adds Kulikowski as chief scientific officer |
2022-08-12 19:09 | CC:RVX | Resverlogix Corp | 0.265 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2022-08-12 19:09 | CC:RVX | Resverlogix Corp | 0.265 | SEDAR MD & A815 | SEDAR MD & A |
2022-06-22 01:21 | CC:RVX | Resverlogix Corp | 0.26 | News Release200 | Resverlogix shareholders approve all AGM resolutions |
2022-06-08 10:20 | CC:RVX | Resverlogix Corp | 0.22 | News Release200 | Resverlogix talks BD2-selective BET inhibitor safety |